Morepen Laboratories Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹570Cr
- +34.1% YoY
- +17.5% QoQ
- Net profit
- ₹56Cr
- +409.1% YoY
- +250% QoQ
- Margin
- 14%
- +8 pp YoY
- +9 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Morepen Laboratories Ltd Q1 FY27 key numbers
- Revenue
- Quarterly revenue reported: Rs. 575.31 Cr.
As stated in Morepen Laboratories Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.
Based on Morepen Laboratories Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Quarterly revenue reported: Rs. 575.31 Cr (Page 4). EBITDA for Q1 FY27: Rs. 87.72 Cr, up 207% YoY.
From Morepen Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).
- Manufacturing capacity scaling in four phases:
- Phase 1: 535 KL (completed by Q4 FY26)
- Phase 2: 600 KL (Q2 FY27)
- Phase 3: 800 KL (FY29)
- Phase 4: 1000 KL (Q2 FY28) and 1200 KL (FY30) (Page 11).
2 more points from Morepen Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Morepen Laboratories Ltd's call on order book
Create a free account to keep reading this call
Morepen Laboratories Ltd — Quarterly revenue & net profit
Morepen Laboratories Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 570 | 425 | +34.1% | 485 | +17.5% |
| Operating profit (EBITDA) | 83 | 24 | +245.8% | 24 | +245.8% |
| Operating margin | 14% | 6% | +8 pp | 5% | +9 pp |
| Profit before tax | 75 | 16 | +368.8% | 23 | +226.1% |
| Net profit (PAT) | 56 | 11 | +409.1% | 16 | +250% |
| EPS (₹) | 1.03 | 0.20 | +415% | 0.29 | +255.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q1 FY27 results?
Quarterly revenue reported: Rs. 575.31 Cr (Page 4). EBITDA for Q1 FY27: Rs. 87.72 Cr, up 207% YoY.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
